Mara Coyle

Dr. Mara Coyle


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
KKKarol Kaltenbach
Karol Kaltenbach
KOKevin E. O’gRady
Kevin E. O’gRady
SHSarah H. Heil
Sarah H. Heil
ASAmy L. Salisbury
Amy L. Salisbury
MCMara Coyle
Mara Coyle
HJHendrée E. Jones
Hendrée E. Jones
Methadone and buprenorphine are recommended to treat opioid use disorders during pregnancy. However, the literature on the relationship between longer-term effects of prenatal exposure to these medications and childhood development is both spare and inconsistent. Participants were 96 children and their mothers who participated in MOTHER, a randomized controlled trial of opioid-agonist pharmacotherapy during pregnancy. The present study examined child growth parameters, cognition, language abilities, sensory processing, and temperament from 0 to 36 months of the child's life. Maternal perceptions of parenting stress, home environment, and addiction severity were also examined. Tests of mean differences between children prenatally exposed to methadone vs. buprenorphine over the three-year period yielded 2/37 significant findings for children. Similarly, tests of mean differences between children treated for NAS relative to those not treated for NAS yielded 1/37 significant finding. Changes over time occurred for 27/37 child outcomes including expected child increases in weight, head and height, and overall gains in cognitive development, language abilities, sensory processing, and temperament. For mothers, significant changes over time in parenting stress (9/17 scales) suggested increasing difficulties with their children, notably seen in increasing parenting stress, but also an increasingly enriched home environment (4/7 scales) CONCLUSIONS: Findings strongly suggest no deleterious effects of buprenorphine relative to methadone or of treatment for NAS severity relative to not-treated for NAS on growth, cognitive development, language abilities, sensory processing, and temperament. Moreover, findings suggest that prenatal opioid agonist exposure is not deleterious to normal physical and mental development.

22 November 2018 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
MCMara Coyle
Mara Coyle
SBSusan B. Brogly
Susan B. Brogly
MAMahmoud S. Ahmed
Mahmoud S. Ahmed
SPStephen W. Patrick
Stephen W. Patrick
HJHendrée E. Jones
Hendrée E. Jones

15 October 2024 in Journal of Perinatology
Verified
Journal Article
Open access
PDF file
MCMara Coyle
Mara Coyle
SOSongthip T. Ounpraseuth
Songthip T. Ounpraseuth
BLBarry Lester
Barry Lester
LDLynne M. Dansereau
Lynne M. Dansereau
ZHZhuopei Hu
Zhuopei Hu
ENEunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network and the NIH Environmental Influences on Child Health Outcomes (ECHO) Program Institutional Development Awards States Pediatric Clinical Trials Networ
Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network and the NIH Environmental Influences on Child Health Outcomes (ECHO) Program Institutional Development Awards States Pediatric Clinical Trials Networ
Objective To predict pharmacotherapy for NOWS based on factors available shortly after birth. Study design A multi-center, retrospective study of 1377 opioid exposed newborns between 2016 and 2017 dichotomized based on pharmacologic treatment (N = 665 treated, N = 712 not treated) was conducted. A multilevel mixed-effect logistic regression model that considered cluster effect from sites determined significant maternal and newborn factors associated with pharmacotherapy, which were combined in a nomogram to predict probability of treatment for infants at each participating site. Results Factors predictive of treatment were: no breastmilk (1.76, 1.30–2.39; p < 0.001), male sex (1.39, 1.05–1.83; p = 0.021), polysubstance exposure (1.53, 1.15–2.06; p = 0.004), inadequate prenatal care (1.51, 1.07–2.13; p < 0.018) and Methadone (6.08, 4.03–9.27; p < 0.001) or Buprenorphine (1.86, 1.29–2.69; p < 0.001). A site-specific nomogram provided the probability of treatment for individual newborns. Conclusion Six factors available shortly after birth can be combined to predict site-specific use of medication for NOWS. If confirmed, the nomogram may identify at-risk newborns.